Cue Biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body to transform the treatment of cancer, infectious disease and autoimmune disease. This approach leverages a natural immune response with innovative protein engineering to achieve a more controlled immune response providing greater patient benefit while reducing toxicity — areas that have traditionally challenged broadly-acting immunotherapies on the market. In a push to move new safe and efficacious immunotherapies to patients, Cue Biopharma has scaled and grown into a clinical-stage company by expanding its development work in-house.
Number of employees: 51 – 250
Location: Cambridge, MA
Non-standardized data capture
Excel sheets were flexible but difficult to manage at scale. This led to tedious data reconciliation when attempting larger analysis.
Barriers to communication and handoffs between teams
Rapid scaling, combined with the difficulty inherent in bridging research and development, led to collaboration challenges.
Growing into early development
Cue Biopharma wanted to evolve into a clinical-stage organization and needed to put in place the digital infrastructure necessary to do so.